香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Hygeia Healthcare Holdings Co., Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 海 吉 亞 醫 療 控 股 有 限 公 司 （股 份 代 號：6078） 自願性公告 二零二五年中期業績簡報 本公告乃由海吉亞醫療控股有限公司（「本公司」）自願作出。 為使本公司股東及潛在投資者能夠更深入、更全面地了解其二零二五年中期 業績及業務營運，本公司將於二零二五年八月二十九日上午八時三十分（香港 時間）召開電話會議，屆時將就本公司財務業績及業務營運進行簡報（「簡報」）。 本公司股東及潛在投資者可於預定時間通過以下撥入信息參加電話會議： | 撥入URL： | https://s.comein.cn/ctmysq3k | | --- | --- | | | 請使用上文所提供的鏈接以於電話會議舉行前完成網 | | | 上登記程序。 | | 電話撥入號碼： | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Hygeia Healthcare Holdings Co., Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 海 吉 亞 醫 療 控 股 有 限 公 司 （股 份 代 號：6078） 截至二零二五年六月三十日止六個月 中期業績公告 財務摘要 截至二零二五年六月三十日止六個月，本集團的收入為人民幣1,989.7百萬元， 較二零二四年同期減少16.5%。 截至二零二五年六月三十日止六個月，本集團的淨利潤為人民幣245.8百萬元， 較二零二四年同期減少36.2%。 截至二零二五年六月三十日止六個月，本集團的非國際財務報告準則經調整 淨利潤(1)為人民幣262.5百萬元，較二零二四年同期減少34.5%。 截至二零二五年六月三十日止六個月，本集團的經營活動所得現金淨額為人 民幣455.7百萬元，較二零二四年同期增加29.9%。 截至二零二五年六月三十日止六個月，本集團的自由現金流 ...

格隆汇8月18日丨海吉亚医疗(06078.HK)公布，公司将于2025年8月28日召开董事会会议，以（其中包 括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议 （如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 海吉亞醫療控股有限公司 主席 朱義文先生 Hygeia Healthcare Holdings Co., Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 海 吉 亞 醫 療 控 股 有 限 公 司 （股 份 代 號：6078） 董事會會議日期 海吉亞醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此公佈， 董事會會議將於二零二五年八月二十八日（星期四）舉行，藉以（其中包括）考 慮及批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業 績及其發佈，並考慮建議派發中期股息（如有）。 香港，二零二五年八月十八日 截至本公告日期，董事會包括主席兼執行董事朱義文先生；執行董事任愛先生、程歡歡女士、 張文山先生及姜蕙女士；以及獨立非執行董事葉長青先生、趙淳先生及張國忠先生。 ...

Group 1: Hong Kong Stocks - Ascentage Pharma-B (06855) opened over 5% higher after receiving FDA and EMA approval for its drug, Lisenglitazone, for high-risk MDS in Phase III clinical trials [1] - Haijia Medical (06078) fell over 5% following a profit warning, expecting a mid-term net profit decline of approximately 34% to 39% due to factors like centralized procurement and increased depreciation from new hospitals [1] - Hua Hong Semiconductor (01347) dropped over 6% as it announced plans to acquire a controlling stake in Shanghai Huali Microelectronics to address industry competition [1] - Zhonghui Biotech-B (02627) rose over 8% after receiving IND approval for its recombinant respiratory syncytial virus vaccine in both the US and China [1] - NetDragon (00777) surged over 10% after forming a strategic alliance with Zhongke Wenge to promote AI technologies abroad [1] - Great Wall Motors (02333) increased over 12% following the completion of its factory in Brazil, with an initial production capacity of 30,000 vehicles per year [1] - Yuewen Group (00772) rose over 20% as its first-half performance exceeded expectations, benefiting from growth in licensing business and steady performance of short dramas [1] Group 2: Other Notable Stocks - Huirui Group (00806) increased over 8% after reporting first-half results that met market expectations and is applying for MRF mutual recognition for other products [2] - Soundon Technology (02495) surged nearly 30% after announcing a projected net profit exceeding 50 million yuan for the first half, marking a turnaround from losses [2] - Robotics concept stocks saw significant gains, with Jinshang Machine Tool (01651) up over 11% and Lijin Technology (00558) up over 3% [2] Group 3: US Stocks - Intel (INTC.US) rose 2.93% amid reports of negotiations with the Trump administration for government investment to support domestic manufacturing [3] - Hesai Technology (HSAI.US) increased 9.73% after reporting over 50% year-on-year revenue growth for Q2 2025 [3] - UnitedHealth (UNH.US) surged 11.98% following Berkshire Hathaway's new investments in the company [3] - NIO (NIO.N) rose 8.09% as it announced the upcoming launch of its new ES8 model [4] - Xunlei (XNET.US) continued to rise by 26.53% after reporting a 30.6% year-on-year revenue increase for Q2 2025 [5]

Core Viewpoint - Haisong Medical (06078) issued a profit warning, expecting a significant decline in mid-term net profit by approximately 34% to 39% year-on-year, leading to a drop of over 5% in stock price [1] Financial Performance Summary - For the six months ending June 30, 2025, the company anticipates a revenue decrease of about 15% to 17% compared to the same period last year [1] - The expected net profit decline is projected to be around 34% to 39% year-on-year [1] - Adjusted net profit, according to non-International Financial Reporting Standards, is expected to decrease by approximately 32% to 37% compared to the previous year [1] - Operating cash flow is expected to improve by about 28% to 32% year-on-year [1] Industry Impact Summary - The decline in revenue and profit is primarily attributed to industry factors such as centralized procurement, DRG payment reforms, and macroeconomic influences [1] - The increase in depreciation and amortization from newly opened hospitals also contributed to the financial downturn [1]

Core Viewpoint - Hai Jiaya Medical (06078) issued a profit warning, leading to a decline of over 5% in its stock price, currently trading at HKD 15.22 with a transaction volume of HKD 52.01 million [1] Financial Performance Summary - For the six months ending June 30, 2025, the company expects a revenue decline of approximately 15% to 17% compared to the same period last year [1] - Net profit is anticipated to decrease by about 34% to 39% year-on-year [1] - Adjusted net profit, based on non-International Financial Reporting Standards, is projected to fall by around 32% to 37% compared to the previous year [1] - Cash generated from operating activities is expected to increase by approximately 28% to 32% year-on-year [1] Industry Impact Summary - The decline in revenue, net profit, and adjusted net profit is primarily attributed to industry factors such as centralized procurement, DRG payment reforms, and macroeconomic influences [1] - The increase in depreciation and amortization from newly opened hospitals also contributed to the financial downturn [1]

本文源自：金融界AI电报 海吉亚医疗(06078.HK)发布公告，截至2025年6月30日止六个月，预计：公司收入较去年同期下降约 15%至17%;净利润较去年同期下降约34%至39%;非国际财务报告准则经调整净利润1较去年同期下降约 32%至37%;及经营活动所得现金净额较去年同期提升约28%至32%。 ...

Group 1 - The company expects a revenue decline of approximately 15% to 17% and a net profit decline of about 34% to 39% for the six months ending June 30, 2025 compared to the same period last year [1] - The decrease in revenue and net profit is primarily due to industry impacts such as centralized procurement, DRG payment reform, macroeconomic influences, and increased depreciation from newly opened hospitals [1] - The company anticipates a decrease in trade receivables by approximately 10% to 11% and a reduction in total liabilities by about 4.5% to 5.5% as of June 30, 2025 [1] Group 2 - The company aims to enhance service processes to meet diverse health needs and improve patient satisfaction while maintaining a focus on operational efficiency and shareholder returns [2] - The company expresses confidence in the long-term development prospects of the industry and itself [2] - Capital expenditures are expected to decline by approximately 28% to 29% compared to the same period last year, while free cash flow is projected to significantly improve [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Hygeia Healthcare Holdings Co., Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 海 吉 亞 醫 療 控 股 有 限 公 司 （股 份 代 號：6078） 盈利預警 海吉亞醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571 章《證券及期貨條例》第XIVA部項下之內幕消息條文（定義見上市規則）作出本 公告。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，基於 對本集團截至2025年6月30日止六個月未經審核綜合管理賬目（按國際財務報告 準則(IFRS)編製）的初步評估及董事會目前可得資料，預計： 1 本集團將「非國際財務報告準則經調整淨利潤」定義為經扣除(i)股份支付薪酬開支；(ii) 收購醫院資產評估增值所產生的折舊及攤銷 ...